Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$61.80 - $113.51
Previous CloseN/A
Volume65.93K
Average Volume (3M)501.75K
Market Cap
$5.58B
Enterprise Value$5.55B
Total Cash (Recent Filing)$145.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 08, 2025EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding66,162,670
10 Day Avg. Volume669,304
30 Day Avg. Volume501,755
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-22.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-19.80
Forecast
1Y Price Target
$111.13Price Target Upside44.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Nuvalent News
---
Bulls Say, Bears Say
Bulls Say
Drug Launch And ApprovalThe updated timeline suggests faster-than-expected patient enrollment and likely sooner-than-expected launch for zidesamtinib in ROS1+ NSCLC by early-26.
Financial StabilityThe company reported cash and cash equivalents of $1.1bn, which they estimate will provide a cash runway into 2028.
Market DemandNuvalent has implemented Expanded Access Programs (EAP) for zidesamtinib and neladakib, which indicates a high demand for these treatments among patients and physicians.
Bears Say
Safety ConcernsManagement noted some CNS signals and GI toxicity with taletrectinib that could be potentially challenging on safety.
Trial LimitationsPretreated ROS1+ NSCLC patients are no longer being enrolled onto ARROS-1, which might limit the evaluation of new data.
---
Ownership Overview
32.98% Insiders
21.21% Mutual Funds
0.03% Other Institutional Investors
35.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $61.80 and its highest was $113.51 in the past 12 months.
What is Nuvalent’s market cap?
Nuvalent’s market cap is $5.58B.
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Feb 27, 2025. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.076 by $0.026.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -1.11.
How many shares outstanding does Nuvalent have?
Nuvalent has 66,162,670 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.076. Following the earnings report the stock price went down -2.765%.
Which hedge fund is a major shareholder of Nuvalent?
Currently, no hedge funds are holding shares in NUVL
---
Nuvalent Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$111.13 (44.06% Upside)
$111.13 (44.06% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $110.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.64%
12-Months-Change
Fundamentals
Return on Equity
-29.46%
Trailing 12-Months
Asset Growth
55.90%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
---
NUVL Stock 12 Month Forecast
Average Price Target
$111.13
▲(44.06% Upside)
Technical Analysis
Best Analysts Covering NUVL
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+26.57%
reiterated a buy rating 26 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +26.57% per trade.
---